Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 2
2013 1
2014 4
2016 2
2018 1
2019 2
2020 2
2021 4
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Trastuzumab emtansine: mechanisms of action and drug resistance.
Barok M, Joensuu H, Isola J. Barok M, et al. Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621. Breast Cancer Res. 2014. PMID: 24887180 Free PMC article. Review.
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. ...The mechanisms of resistance are incompletely understood, but m …
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when adminis …
Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond.
García-Alonso S, Ocaña A, Pandiella A. García-Alonso S, et al. Trends Cancer. 2020 Feb;6(2):130-146. doi: 10.1016/j.trecan.2019.12.010. Epub 2020 Jan 21. Trends Cancer. 2020. PMID: 32061303 Review.
The approval of ado-trastuzumab emtansine (T-DM1) for clinical use represented a turning point both in HER2-positive breast cancer treatment and antibody-drug conjugate (ADC) technology. ...Conceptually, many lessons can be learned from this ADC. Under …
The approval of ado-trastuzumab emtansine (T-DM1) for clinical use represented a turning point both in HER2-positive br …
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, Chen L, Zhu Y, Guo C, Shi J, Yu D. Xu Z, et al. Eur J Med Chem. 2019 Dec 1;183:111682. doi: 10.1016/j.ejmech.2019.111682. Epub 2019 Sep 6. Eur J Med Chem. 2019. PMID: 31563805 Review.
The off-target effect has an excellent therapeutic prospect. Among them, ado-trastuzumab emtansine (T-DM1) is a successful example of targeting human epidermal growth factor receptor-2 (HER2). ...The two ADCs described here use the same antibody as T-DM1, but …
The off-target effect has an excellent therapeutic prospect. Among them, ado-trastuzumab emtansine (T-DM1) is a success …
Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges.
Guidi L, Pellizzari G, Tarantino P, Valenza C, Curigliano G. Guidi L, et al. Cancers (Basel). 2023 Feb 10;15(4):1130. doi: 10.3390/cancers15041130. Cancers (Basel). 2023. PMID: 36831473 Free PMC article. Review.
The treatment of HER2-positive metastatic breast cancer (mBC) with Trastuzumab emtansine (T-DM1) and Trastuzumab deruxtecan (T-DXd), two antibody-drug conjugates (ADCs) targeting HER2, is burdened by progression of disease related to the acquisition of …
The treatment of HER2-positive metastatic breast cancer (mBC) with Trastuzumab emtansine (T-DM1) and Trastuzumab deruxt …
Trastuzumab-deBouganin Conjugate Overcomes Multiple Mechanisms of T-DM1 Drug Resistance.
Dillon RL, Chooniedass S, Premsukh A, Adams GP, Entwistle J, MacDonald GC, Cizeau J. Dillon RL, et al. J Immunother. 2016 Apr;39(3):117-26. doi: 10.1097/CJI.0000000000000115. J Immunother. 2016. PMID: 26938945
Despite these improvements, most patients eventually relapse due to complex mechanisms of resistance often associated with small molecule chemotherapeutics. Therefore, identifying payloads with different mechanisms of action (MOA) is critical for incre …
Despite these improvements, most patients eventually relapse due to complex mechanisms of resistance often associated with sma …
Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.
Sadeghi S, Olevsky O, Hurvitz SA. Sadeghi S, et al. Pharmgenomics Pers Med. 2014 Oct 15;7:329-38. doi: 10.2147/PGPM.S47524. eCollection 2014. Pharmgenomics Pers Med. 2014. PMID: 25378946 Free PMC article. Review.
PURPOSE: This article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clinical data relating to its use for human growth factor receptor 2 (HER2)-positive breast cancer, potential pathways of resistance, and ongoing st …
PURPOSE: This article reviews the mechanism of action of trastuzumab emtansine (T-DM1), existing clinical data r …
An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.
Gandullo-Sánchez L, Pandiella A. Gandullo-Sánchez L, et al. Cancer Lett. 2023 Feb 1;554:216024. doi: 10.1016/j.canlet.2022.216024. Epub 2022 Nov 29. Cancer Lett. 2023. PMID: 36455759 Free article.
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved in 2013 to treat HER2+ breast cancer. Despite its efficacy in the clinic, some patients exhibit intrinsic or acquired resistance to such ADC. To characterize mechani …
Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate (ADC) that was approved in 2013 to treat HER2+ breast cance …
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs.
Díaz-Rodríguez E, Gandullo-Sánchez L, Ocaña A, Pandiella A. Díaz-Rodríguez E, et al. Cancers (Basel). 2021 Dec 29;14(1):154. doi: 10.3390/cancers14010154. Cancers (Basel). 2021. PMID: 35008318 Free PMC article. Review.
Two anti-HER2 ADCs have reached the clinic: trastuzumab-emtansine and, more recently, trastuzumab-deruxtecan. In addition, several other HER2-targeted ADCs are in preclinical or clinical development, some of them with promising signs of activity. In the prese …
Two anti-HER2 ADCs have reached the clinic: trastuzumab-emtansine and, more recently, trastuzumab-deruxtecan. In additi …
HER2-positive breast cancer: Current and new therapeutic strategies.
Escrivá-de-Romaní S, Arumí M, Bellet M, Saura C. Escrivá-de-Romaní S, et al. Breast. 2018 Jun;39:80-88. doi: 10.1016/j.breast.2018.03.006. Epub 2018 Apr 6. Breast. 2018. PMID: 29631097 Review.
Inevitably, despite these therapeutic advances most patients progress on therapy due to primary or acquired resistance or because of an incorrect HER2 positivity assessment. Hence, it is crucial to correctly categorize HER2 amplified tumors and define mechanisms of …
Inevitably, despite these therapeutic advances most patients progress on therapy due to primary or acquired resistance or because of …
Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Tapia M, Hernando C, Martínez MT, Burgués O, Tebar-Sánchez C, Lameirinhas A, Ágreda-Roca A, Torres-Ruiz S, Garrido-Cano I, Lluch A, Bermejo B, Eroles P. Tapia M, et al. Cancers (Basel). 2023 Sep 12;15(18):4522. doi: 10.3390/cancers15184522. Cancers (Basel). 2023. PMID: 37760491 Free PMC article. Review.
Moreover, trastuzumab deruxtecan has enhanced the efficacy of trastuzumab emtansine, and the new drug trastuzumab duocarmazine is currently undergoing clinical trials to assess its effect. ...Clinical research should be strengthened along with t …
Moreover, trastuzumab deruxtecan has enhanced the efficacy of trastuzumab emtansine, and the new drug trastuz …
25 results